Mississippi Cannabis Law at a Crossroads: State Setback, Federal Shift
Mississippi’s medical cannabis program has recently reached a standstill—just as federal policy begins moving in a very different direction.
Earlier this year, Mississippi lawmakers passed legislation that would have expanded the state’s medical cannabis program, making it easier for patients to access treatment and giving physicians more flexibility in recommending it. However, that momentum came to a halt when Governor Tate Reeves vetoed the bills, citing concerns about loosening restrictions too quickly. The Legislature did not override the veto, leaving Mississippi’s current medical cannabis framework unchanged for now.
At the same time, on the federal level, the conversation around cannabis is shifting in a meaningful way. Under the Controlled Substances Act, cannabis has long been classified as a Schedule I substance, a category reserved for drugs with no accepted medical use and a high potential for abuse. That classification has shaped everything from research limitations to how businesses are taxed.
Federal regulators have now taken steps toward reclassifying certain cannabis products to Schedule III. Importantly, this change does not legalize cannabis at the federal level. Rather, it reflects a shift in how certain state-approved medical cannabis and FDA-approved cannabis-derived products may be treated under federal law. Recreational cannabis remains illegal at the federal level.
Taken together, these developments highlight a reality that patients, providers, and businesses are continuing to navigate: cannabis law in the United States is not evolving in a straight line.
In Mississippi, the governor’s veto means the proposed changes—such as removing potency caps on certain products, extending certification timelines, and expanding physician discretion—are not moving forward at this time. Patients remain subject to existing qualification requirements, physicians must continue operating within current statutory limits, and cannabis businesses will not see immediate regulatory relief at the state level.
Meanwhile, the potential federal shift carries a different kind of impact. If certain cannabis products are ultimately treated as Schedule III substances, one of the most significant changes could come in the form of tax treatment. Current federal law prevents many cannabis businesses from deducting ordinary business expenses, creating a heavy financial burden. A reclassification could, over time, allow for those deductions, improving sustainability for operators across the industry—though implementation and scope remain important considerations.
The shift could also encourage additional research and broader acceptance within the medical community. For healthcare providers, this may lead to more informed discussions with patients and, over time, a more structured approach to cannabis as part of treatment plans. Still, even with federal movement, physicians must continue to follow state-specific laws when recommending cannabis.
For patients, the picture is mixed. While federal changes may signal progress and greater recognition of medical use, access in Mississippi remains tied to the state’s current, more limited framework. In other words, the federal government may be moving forward, but Mississippi is, at least temporarily, holding its position.
This kind of disconnect between state and federal law is not new in the cannabis space, but it is becoming more pronounced as federal policy evolves. Businesses, providers, and patients alike must continue to operate in a system where compliance depends heavily on jurisdiction and where changes at one level do not always translate to immediate changes at another.
For now, Mississippi’s cannabis program remains as it was, while the broader legal landscape continues to shift around it. Additional legislative efforts at the state level and further federal action are likely, making this an area to watch closely in the months ahead.
HAT Law Firm continues to monitor developments in the cannabis industry. If you have questions regarding cannabis law or compliance, please contact HAT Law’s Cannabis Legal Team: Julie Mitchell, J.D., LL.M., jmitchell@hatlawfirm.com, 601-707-4039.
Disclaimer: This article is for informational purposes only and does not constitute legal advice. Readers should consult legal counsel regarding specific legal or compliance questions.